Avadel Pharmaceuticals PLC AVDL.OQ AVDL.O is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
The Dublin-based company is expected to report a 593.0% increase in revenue to $48.607 million from $7.01 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
LSEG's mean analyst estimate for Avadel Pharmaceuticals PLC is for a loss of 6 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Avadel Pharmaceuticals PLC is $24.00, above its last closing price of $15.72.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jan. 1 0001 | -0.17 | -0.16 | -0.14 | Beat | 10 |
Mar. 31 0001 | -0.20 | -0.21 | -0.30 | Missed | -44.4 |
Dec. 31 2023 | -0.23 | -0.26 | -0.29 | Missed | -11.8 |
Jan. 1 0001 | -0.38 | -0.37 | -0.41 | Missed | -10.1 |
Jun. 30 2023 | -0.38 | -0.38 | -0.83 | Missed | -116 |
Jan. 1 0001 | -0.34 | -0.38 | -0.48 | Missed | -27.4 |
Dec. 31 2022 | -0.30 | -0.27 | -0.46 | Missed | -69.7 |
Sep. 30 2022 | -0.21 | -0.25 | -0.33 | Missed | -30.3 |
This summary was machine generated November 8 at 16:31 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments